JohnCurfmanNP

Journal Articles

• Epigenetics meets genetics in acute myeloid leukemia: Clinical impact of a novel seven-gene score  
  Marcucci, G., Yan, P., Maharry, K., Frankhouser, D., Nicolet, D., Metzeler, K. H., & Bloomfield, C. D., Journal of Clinical Oncology, 1/1/2014
• Inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations  
  Schwind, S., Edwards, C. G., Nicolet, D., Mrozek, K., Maharry, K., Wu, Y. Z., & Bloomfield, C. D., Blood, 1/1/2013
• Methods for high-throughput MethylCap-seq data analysis  
  Rodriguez, B. A., Frankhouser, D., Murphy, M., Trimarchi, M., Tam, H. H., Curfman, J., & Bundschuh, R., BMC Genomics, 1/26/2012
• Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia  
  Yan, P., Frankhouser, D., Murphy, M., Tam, H. H., Rodriguez, B., Curfman, J., & Marcucci, G., Blood, 1/1/2012
• Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia  
  Blum, W., Schwind, S., Tarighat, S. S., Geyer, S., Eisfeld, A. K., Whitman, S., & Marcucci, G., Blood, 1/1/2012
• TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A cancer and leukemia group B study  
  Metzeler, K. H., Maharry, K., Radmacher, M. D., Mrozek, K., Margeson, D., Becker, H., Curfman, J., …& Bloomfield, C. D, Journal of Clinical Oncology, 1/1/2011
• Dose escalation of lenalidomide in relapsed or refractory acute leukemias  
  Blum, W., Klisovic, R. B., Becker, H., Yang, X., Rozewski, D. M., Phelps, M. A., & Byrd, J. C., Journal of Clinical Oncology, 1/1/2010
• microRNA modulation of circadian-clock period and entrainment  
  Cheng, H. Y., Papp, J. W., Varlamova, O., Dziema, H., Russell, B., Curfman, J. P., & Obrietan, K, Neuron, 1/1/2007
• Join now to see all